| Primary |
| Sedation |
28.6% |
| Pneumonia |
21.4% |
| Antibiotic Therapy |
7.1% |
| Anticoagulant Therapy |
7.1% |
| Cardiovascular Disorder |
7.1% |
| Ill-defined Disorder |
4.8% |
| Prophylaxis |
4.8% |
| Pseudomonas Infection |
4.8% |
| Urinary Tract Infection Pseudomonal |
4.8% |
| Atrial Thrombosis |
2.4% |
| Culture |
2.4% |
| Drug Use For Unknown Indication |
2.4% |
| Serratia Bacteraemia |
2.4% |
|
| Convulsion |
18.8% |
| Thrombocytopenia |
12.5% |
| Acute Respiratory Distress Syndrome |
6.3% |
| Blood Creatinine Increased |
6.3% |
| Coma |
6.3% |
| Diarrhoea |
6.3% |
| Drug Level Decreased |
6.3% |
| Loeffler's Syndrome |
6.3% |
| Mental Status Changes |
6.3% |
| Pneumonia |
6.3% |
| Rash |
6.3% |
| Renal Tubular Acidosis |
6.3% |
| Substance Abuse |
6.3% |
|
| Secondary |
| Product Used For Unknown Indication |
49.6% |
| Drug Use For Unknown Indication |
6.5% |
| Pneumonia |
6.2% |
| Tracheobronchitis |
3.9% |
| Antibiotic Therapy |
3.1% |
| Fusarium Infection |
2.8% |
| Infection |
2.8% |
| Urinary Tract Infection |
2.6% |
| Immunosuppressant Drug Therapy |
2.5% |
| Acinetobacter Infection |
2.3% |
| Immunosuppression |
2.2% |
| Septic Shock |
2.0% |
| Postoperative Wound Infection |
1.9% |
| Sepsis |
1.9% |
| Acute Myeloid Leukaemia |
1.7% |
| Antifungal Prophylaxis |
1.7% |
| Febrile Neutropenia |
1.7% |
| Mycobacterium Abscessus Infection |
1.6% |
| Wound Infection Staphylococcal |
1.6% |
| Pyrexia |
1.4% |
|
| Death |
14.7% |
| Septic Shock |
9.5% |
| Renal Failure Acute |
7.4% |
| Liver Injury |
6.3% |
| Pneumonia |
6.3% |
| Toxic Epidermal Necrolysis |
6.3% |
| Respiratory Failure |
5.3% |
| Systemic Candida |
5.3% |
| Thrombocytopenia |
5.3% |
| Pancytopenia |
4.2% |
| Sepsis |
4.2% |
| Subacute Hepatic Failure |
4.2% |
| Agranulocytosis |
3.2% |
| Drug Ineffective |
3.2% |
| Hepatocellular Injury |
3.2% |
| Treatment Failure |
3.2% |
| Blood Creatinine Increased |
2.1% |
| Blood Potassium Increased |
2.1% |
| Clostridium Difficile Colitis |
2.1% |
| Drug Interaction |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.9% |
| Drug Use For Unknown Indication |
19.6% |
| Acute Myeloid Leukaemia |
5.7% |
| Prophylaxis |
5.4% |
| Pneumonia |
4.8% |
| Sedation |
3.0% |
| Pyrexia |
2.9% |
| Hypertension |
2.8% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.7% |
| Infection Prophylaxis |
2.5% |
| Antifungal Prophylaxis |
2.5% |
| Febrile Neutropenia |
2.4% |
| Analgesic Therapy |
2.4% |
| Sepsis |
2.3% |
| Infection |
2.2% |
| Antibiotic Prophylaxis |
2.2% |
| Peritonitis |
2.1% |
| Aspergillosis |
1.9% |
| Medical Diet |
1.9% |
| Antiviral Prophylaxis |
1.7% |
|
| Sepsis |
15.8% |
| Septic Shock |
10.0% |
| Vomiting |
7.6% |
| Pneumonia |
6.5% |
| Respiratory Failure |
6.5% |
| Thrombocytopenia |
5.8% |
| White Blood Cell Count Increased |
5.8% |
| Pyrexia |
5.2% |
| Multi-organ Failure |
4.5% |
| Renal Failure |
4.5% |
| Wound Infection |
3.8% |
| Death |
3.4% |
| Urinary Tract Infection |
3.4% |
| White Blood Cell Count Decreased |
3.1% |
| Drug Ineffective |
2.7% |
| Febrile Neutropenia |
2.4% |
| Pneumatosis Intestinalis |
2.4% |
| Renal Failure Acute |
2.4% |
| Pathogen Resistance |
2.1% |
| Rhabdomyolysis |
2.1% |
|
| Interacting |
| Epilepsy |
50.0% |
| Osteolysis |
50.0% |
|
| Drug Level Decreased |
100.0% |
|
